

## European Pharmacopoeia Commission Secretariat

RZ/PH/2011-03431L  
CV/lke

Strasbourg, 30 May 2011


### CIRCULAR LETTER FOR THE ATTENTION OF THE LIAISON SECTIONS OF THE EUROPEAN PHARMACOPOEIA

Subject: **Resolution AP-CPH (11) 5**

In accordance with the decision taken by the Public Health Committee (Partial Agreement) (CD-P-SP) at its meeting on 1 December 1994\* and the proposal of the European Pharmacopoeia Commission on 3 May 2011, please find enclosed:

- Resolution AP-CPH (11) 5 concerning the rapid implementation on 1 July 2011 in the European Pharmacopoeia of the revised version of the chapter:
- Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (5.2.8)

Do not hesitate to contact me if you need further information.



Mrs Cathie VIELLE  
Secretary to the Commission

cc: National Authorities

*\* Note: Following the decisions taken by the Committee of Ministers at its 1017th meeting, on 6 February 2008, pursuant to which the European Committee on pharmaceuticals and pharmaceutical care (CD-P-PH) would carry out the tasks of the Public Health Committee set out in the Convention on the Elaboration of a European Pharmacopoeia (ETS No. 50), as amended by the Protocol (ETS No. 134), and any reference to the "Public Health Committee" in the said Convention and Protocol should from this date be understood as referring to the European Committee on pharmaceuticals and pharmaceutical care.*